November 1, 2022
Verici Dx’s post-transplant test, Tuteva, to be rebranded as TutiviaTM Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its post-transplant blood test focused on acute rejection, has been rebranded as TutiviaTM. TutiviaTM (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute […]
Keep Reading